Valuation: Impax Laboratories Inc

Market Cap 7.07B 6.28B 5.86B 5.34B 10.08B 680B 10.17B 70.96B 27.5B 347B 26.55B 25.97B 1,115B P/E 2026 *
41.7x
P/E 2027 * 31x
Enterprise Value 9.51B 8.45B 7.88B 7.18B 13.55B 914B 13.68B 95.39B 36.96B 467B 35.69B 34.91B 1,499B EV / Sales 2026 *
3.01x
EV / Sales 2027 * 2.67x
Free-Float
44.36%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2019-07-31
Chief Executive Officer 54 2019-07-31
Director of Finance/CFO 58 2023-11-06
Director TitleAgeSince
Director/Board Member 59 2023-11-06
Director/Board Member 70 2023-11-06
Director/Board Member 52 2023-11-06
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 7.07B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
+0.10%-4.05%+20.54%+41.71% 333B
+0.79%-2.89%+10.57%+32.81% 267B
+0.15%-5.43%-6.17%+8.98% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.39%-3.54%+26.07%+58.65% 410.8B
Weighted average by Cap. -0.23%-3.54%+29.07%+70.57%

Financials

2026 *2027 *
Net sales 3.16B 2.8B 2.62B 2.39B 4.5B 303B 4.54B 31.67B 12.27B 155B 11.85B 11.59B 498B 3.44B 3.06B 2.86B 2.6B 4.91B 331B 4.96B 34.57B 13.39B 169B 12.93B 12.65B 543B
Net income 165M 147M 137M 125M 236M 15.89B 238M 1.66B 643M 8.12B 621M 607M 26.07B 227M 202M 188M 171M 323M 21.81B 326M 2.28B 882M 11.15B 852M 833M 35.78B
Net Debt 2.43B 2.16B 2.02B 1.84B 3.47B 234B 3.5B 24.43B 9.47B 120B 9.14B 8.94B 384B 2.14B 1.9B 1.77B 1.62B 3.05B 206B 3.08B 21.46B 8.31B 105B 8.03B 7.85B 337B
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-